# Janssen-Cilag International NV clinical trials: 67 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 67 trials with Janssen-Cilag International NV as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Janssen-Cilag International NV: 67 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/janssen-cilag-international-nv

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 67
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 67, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 25, 2021 | NCT04940039 | A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings | Janssen-Cilag International NV | Phase 4 | Completed | Schizophrenia | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04940039) |
| April 8, 2020 | NCT04338321 | A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin... | Janssen-Cilag International NV | Phase 3 | Completed | Depressive Disorder, Major | 676 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04338321) |
| May 13, 2019 | NCT03947814 | A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment | Janssen-Cilag International NV | Phase 1 | Terminated | Kidney Failure, Chronic | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03947814) |
| February 25, 2019 | NCT03852160 | A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral... | Janssen-Cilag International NV | Phase 3 | Withdrawn | Depressive Disorder, Treatment-Resistant | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03852160) |
| January 28, 2019 | NCT03818035 | A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis | Janssen-Cilag International NV | Phase 3 | Completed | Psoriasis | 880 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03818035) |
| January 25, 2019 | NCT03816631 | A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment | Janssen-Cilag International NV | Phase 1 | Completed | Hepatic Impairment | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03816631) |
| January 18, 2019 | NCT03809325 | A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate... | Janssen-Cilag International NV | Observational | Completed | Schizophrenia | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03809325) |
| December 7, 2018 | NCT03768609 | A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting... | Janssen-Cilag International NV | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03768609) |
| July 2, 2018 | NCT03574532 | A Study to Determine the Epidemiology and Evaluate the Burden of Disease in Respiratory Syncytial Virus/Human Metapneumovirus and Influenza... | Janssen-Cilag International NV | Observational | Completed | Respiratory Tract Infections | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03574532) |
| June 6, 2018 | NCT03547024 | A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the... | Janssen-Cilag International NV | Phase 1 | Completed | Healthy | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03547024) |
| February 19, 2018 | NCT03437590 | A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using \[18F\]-JNJ-64413739 | Janssen-Cilag International NV | Phase 1 | Completed | Healthy | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03437590) |
| August 15, 2017 | NCT03249402 | A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive... | Janssen-Cilag International NV | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03249402) |
| July 14, 2017 | NCT03218488 | A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis | Janssen-Cilag International NV | Observational | Active not recruiting | Psoriasis | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03218488) |
| May 12, 2017 | NCT03151486 | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55308942 in Healthy Male and Female Participants | Janssen-Cilag International NV | Phase 1 | Completed | Healthy | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03151486) |
| April 10, 2017 | NCT03105986 | A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in... | Janssen-Cilag International NV | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03105986) |
| March 23, 2017 | NCT03088644 | A Study to Investigate P2X7 Receptor Occupancy by JNJ-54175446 With the Newly Developed P2X7 Receptor Positron Emission Tomography (PET)... | Janssen-Cilag International NV | Phase 1 | Completed | Healthy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03088644) |
| January 18, 2017 | NCT03023852 | A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet and Single... | Janssen-Cilag International NV | Phase 1 | Completed | Healthy | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03023852) |
| August 9, 2016 | NCT02860806 | Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a... | Janssen-Cilag International NV | Phase 1 | Completed | Healthy | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02860806) |
| August 2, 2016 | NCT02852395 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274 | Janssen-Cilag International NV | Phase 1 | Completed | Healthy | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02852395) |
| June 24, 2016 | NCT02812251 | Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-61393215 in Healthy Participants | Janssen-Cilag International NV | Phase 1 | Completed | Healthy | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02812251) |
| April 14, 2016 | NCT02737657 | An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan | Janssen-Cilag International NV | Observational | Completed | Diabetes Mellitus, Type 2 | 379 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02737657) |
| March 4, 2016 | NCT02699385 | A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis | Janssen-Cilag International NV | Phase 3 | Terminated | Gastroenteritis | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02699385) |
| October 19, 2015 | NCT02578472 | Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922... | Janssen-Cilag International NV | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02578472) |
| August 5, 2015 | NCT02515955 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participants | Janssen-Cilag International NV | Phase 1 | Completed | Healthy | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02515955) |
| June 19, 2015 | NCT02476058 | A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder | Janssen-Cilag International NV | Phase 1 | Completed | Major Depressive Disorder | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02476058) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 23 |
| Phase 2 | 7 |
| Phase 3 | 24 |
| Phase 4 | 3 |
| Not applicable | 1 |
| Observational | 9 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 61 |
| Terminated | 3 |
| Withdrawn | 1 |
| Active not recruiting | 1 |
| No longer available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Schizophrenia | 11 |
| Hepatitis C | 6 |
| Multiple Myeloma | 6 |
| Hepatitis C, Chronic | 5 |
| Acquired Immunodeficiency Syndrome | 3 |
| Infections | 3 |
| Psoriasis | 3 |
| Agnosia | 3 |
| HIV Infections | 2 |
| Attention Deficit Disorder with Hyperactivity | 2 |
| Recurrence | 2 |
| Pain, Postoperative | 2 |
| Depressive Disorder, Major | 2 |
| Bone Marrow Neoplasms | 2 |
| Pain | 2 |
| Myelodysplastic Syndromes | 1 |
| Myeloproliferative Disorders | 1 |
| Bone Marrow Diseases | 1 |
| Anemia | 1 |
| Depressive Disorder, Treatment-Resistant | 1 |
| Fibrosis | 1 |
| Respiratory Tract Infections | 1 |
| Psychotic Disorders | 1 |
| Neoplasms | 1 |
| Hallux Valgus | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Elementary schools in the United States](https://specstream.ai/data/businesses/elementary-schools/united-states)
- [Blinds and shades companies in the United States](https://specstream.ai/data/businesses/blinds-and-shades-companies/united-states)
- [Venezuelan restaurants in the United States](https://specstream.ai/data/businesses/venezuelan-restaurants/united-states)
- [Pubs in the United States](https://specstream.ai/data/businesses/pubs/united-states)
- [Marketing agencies in the United States](https://specstream.ai/data/businesses/marketing-agencies/united-states)
- [Forestry services in the United States](https://specstream.ai/data/businesses/forestry-services/united-states)
